Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0242339 (dyslipidemia)
 13,927 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A study was made of the content of blood lipids in patients with associated chronic nephritis and arterial hypertension (AH). It has been established that the reduction of arterial pressure as a result of hypotensive therapy (administration of central action drugs, vasodilators of direct action, calcium antagonists, blockers of the angiotensin-transforming enzyme) was followed by a decrease in the blood of the concentration of fatty acids, glycerin, triglycerides, low density lipoproteins, total cholesterol, free cholesterol, phospholipids, characteristics of lipid peroxidation and by the rise of cholesterol concentration in high density lipoproteins. The data obtained are of clinical importance in view of the possibility of correcting dyslipidemia in patients with associated chronic nephritis and arterial hypertension during hypotensive treatment.
 ...
PMID:[Hypotensive therapy and the level of blood lipids in patients with chronic nephritis associated with arterial hypertension]. 279 97

Serum lipids were estimated in patients with renal amyloidosis (RA): 21 with familial Mediterranean fever (FMF) and 24 with secondary renal amyloidosis versus FMF patients without renal dysfunction or having chronic glomerular nephritis. All the RA patients had dyslipidemia of atherogenic nature the severity of which correlated with that of renal disorder. Our results showed the presence of dyslipidemia early during RA course. It is renal involvement that results in dyslipidemia observed in FMF patients.
 ...
PMID:[Blood lipids in renal amyloidosis]. 794 Nov 22

Advances in immunotherapy have improved survival of patients with systemic lupus erythematosus who now face an increasing burden of chronic diseases including that of the kidney. As systemic inflammation is also thought to contribute directly to the progression of chronic kidney disease (CKD), we assessed this risk in patients with lupus, with and without a diagnosis of nephritis, and also identified modifiable risk factors. Accordingly, we enrolled 631 patients (predominantly Caucasian), of whom 504 were diagnosed with lupus within the first year and followed them an average of 11 years. Despite the presence of a chronic inflammatory disease, the rate of decline in renal function of 238 patients without nephritis was similar to that described for non-lupus patient cohorts. Progressive loss of kidney function developed exclusively in patients with lupus nephritis who had persistent proteinuria and dyslipidemia, although only six required dialysis or transplantation. The mortality rate was 16% with half of the deaths attributable to sepsis or cancer. Thus, despite the presence of a systemic inflammatory disease, the risk of progressive CKD in this lupus cohort was relatively low in the absence of nephritis. Hence, as in idiopathic glomerular disease, persistent proteinuria and dyslipidemia (modifiable risks) are the major factors for CKD progression in lupus patients with renal involvement.
 ...
PMID:Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. 2156 55